NASDAQ:BNTX BioNTech (BNTX) Stock Forecast, Price & News $109.25 +0.28 (+0.26%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$108.61▼$110.7650-Day Range$102.58▼$129.6652-Week Range$100.08▼$188.99Volume507,082 shsAverage Volume693,087 shsMarket Capitalization$26.57 billionP/E Ratio4.20Dividend YieldN/APrice Target$171.07 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioNTech MarketRank™ ForecastAnalyst RatingHold2.46 Rating ScoreUpside/Downside56.6% Upside$171.07 Price TargetShort InterestHealthy0.83% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth-57.00%From $6.14 to $2.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector255th out of 987 stocksBiological Products, Except Diagnostic Industry35th out of 160 stocks 4.2 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $171.07, BioNTech has a forecasted upside of 56.6% from its current price of $109.25.Amount of Analyst CoverageBioNTech has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.83% of the outstanding shares of BioNTech have been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently increased by 5.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 1.4 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for BioNTech this week, compared to 9 articles on an average week.Search InterestOnly 29 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.29% of the stock of BioNTech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease by -57.00% in the coming year, from $6.14 to $2.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 4.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.00.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 4.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 96.59.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioNTech (NASDAQ:BNTX) StockBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address BNTX Stock News HeadlinesJune 9, 2023 | markets.businessinsider.comBioNTech SE (BNTX) Gets a Buy from H.C. WainwrightJune 7, 2023 | msn.comPfizer, Moderna face new patent lawsuits over COVID vaccine techJune 9, 2023 | Behind the Markets (Ad)[Strong Buy Alert] Is this laser stock in your portfolio?🚨 [Strong Buy Alert] Is this laser stock in your portfolio? There are very few opportunities like this in today's bear market... But our analysts identified a tiny defense company landing billions of dollars in contracts every year.June 6, 2023 | finance.yahoo.comNovavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging VariantsJune 2, 2023 | finance.yahoo.comWhy Shares of BioNTech Rose FridayJune 2, 2023 | msn.comBioNTech reports promising data on BNT316, Phase 3 trial slated for Q3June 2, 2023 | markets.businessinsider.comBioNTech SE (BNTX) Gets a Hold from Goldman SachsJune 2, 2023 | finance.yahoo.comBioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer TreatmentJune 9, 2023 | Vector Vest (Ad)Free Stock Analysis Report: Get Buy, Sell, or Hold RecommendationGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. June 2, 2023 | it.tmcnet.comBioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCOJune 1, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for BioNTechJune 1, 2023 | americanbankingnews.comBioNTech (NASDAQ:BNTX) PT Lowered to $181.00June 1, 2023 | americanbankingnews.comShort Interest in BioNTech SE (NASDAQ:BNTX) Rises By 5.2%May 30, 2023 | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Receives $172.20 Consensus Price Target from AnalystsMay 28, 2023 | fool.comBioNTech Se (NASDAQ: BNTX)May 26, 2023 | msn.comEU negotiates extended COVID-19 vaccine contract with Pfizer-BioNTechMay 26, 2023 | msn.comPfizer and BioNTech reach a deal with EU to change covid vaccine contractMay 26, 2023 | msn.comPfizer, BioNTech agree to revise EU COVID vaccine dealMay 26, 2023 | msn.comAmended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced PurchasesMay 26, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for BioNTech SE Issued By HC Wainwright (NASDAQ:BNTX)May 25, 2023 | finance.yahoo.comBioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 CasesMay 25, 2023 | seekingalpha.comBioNTech readying next COVID shot in line WHO guidanceMay 25, 2023 | msn.comBioNTech readying next COVID shot in line with WHO guidanceMay 25, 2023 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Price Target Cut to $198.00May 22, 2023 | seekingalpha.comBioNTech: Able To Tap Into High Medical Need PD-L1 Refractory NSCLC MarketMay 20, 2023 | americanbankingnews.comDeutsche Bank Aktiengesellschaft Trims BioNTech (NASDAQ:BNTX) Target Price to $120.00May 19, 2023 | msn.comCureVac’s Lawsuit against Pfizer, BioNTech Picks Up SteamSee More Headlines BNTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Company Calendar Last Earnings5/08/2023Today6/09/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees4,530Year Founded2008Price Target and Rating Average Stock Price Forecast$171.07 High Stock Price Forecast$260.00 Low Stock Price Forecast$120.00 Forecasted Upside/Downside+56.6%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$26.01 Trailing P/E Ratio4.20 Forward P/E Ratio17.79 P/E GrowthN/ANet Income$9.94 billion Net Margins51.03% Pretax Margin69.48% Return on Equity32.52% Return on Assets27.56% Debt Debt-to-Equity Ratio0.01 Current Ratio12.95 Quick Ratio12.68 Sales & Book Value Annual Sales$18.24 billion Price / Sales1.46 Cash Flow$41.38 per share Price / Cash Flow2.64 Book Value$87.07 per share Price / Book1.25Miscellaneous Outstanding Shares243,210,000Free Float196,518,000Market Cap$26.57 billion OptionableNot Optionable Beta0.22 Social Links Key ExecutivesProf. Ugur Sahin M.D. (Age 58)Co-Founder, CEO & Chair of the Management Board Comp: $477.72kDr. Ozlem Tureci M.D. (Age 56)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $887.96kProf. Christoph Hubert Huber M.D. (Age 79)Ph.D., Co-Founder & Member of Supervisory Board Comp: $85.69kMr. Jens H. Holstein (Age 60)CFO & Member of Management Board Comp: $935.09kDr. Sierk Poetting Ph.D. (Age 50)MD, COO & Member of Management Board Comp: $982.22kMr. Ryan Richardson (Age 44)Chief Strategy Officer, MD & Member of Management Board Comp: $474.51kMr. Sean Marett (Age 58)Chief Bus. Officer, Chief Commercial Officer & Member of Management Board Comp: $910.45kSylke Maas Ph.D.VP of Investor Relations and Bus. StrategyDr. James Timothy Patrick Ryan Ph.D.Sr. VP & Gen. CounselMichael BoehlerMD & Head of Global External CommunicationsMore ExecutivesKey CompetitorsargenxNASDAQ:ARGXSeagenNASDAQ:SGENBio-TechneNASDAQ:TECHQiagenNYSE:QGENBiogenNASDAQ:BIIBView All CompetitorsInstitutional OwnershipMacquarie Group Ltd.Sold 3,894 shares on 6/1/2023Ownership: 0.015%ProShare Advisors LLCSold 1,123 shares on 5/26/2023Ownership: 0.003%Ameriprise Financial Inc.Bought 5,371 shares on 5/22/2023Ownership: 0.020%CTC LLCBought 119 shares on 5/22/2023Ownership: 0.000%JPMorgan Chase & Co.Sold 4,029 shares on 5/18/2023Ownership: 0.010%View All Institutional Transactions BNTX Stock - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price forecast for 2023? 13 Wall Street research analysts have issued 12 month price objectives for BioNTech's shares. Their BNTX share price forecasts range from $120.00 to $260.00. On average, they anticipate the company's share price to reach $171.07 in the next year. This suggests a possible upside of 56.2% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2023? BioNTech's stock was trading at $150.22 at the beginning of the year. Since then, BNTX shares have decreased by 27.1% and is now trading at $109.50. View the best growth stocks for 2023 here. Are investors shorting BioNTech? BioNTech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,020,000 shares, an increase of 5.2% from the April 30th total of 1,920,000 shares. Based on an average daily volume of 699,600 shares, the short-interest ratio is currently 2.9 days. View BioNTech's Short Interest. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our BNTX earnings forecast. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings data on Monday, May, 8th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $0.18 by $1.87. The company earned $1.28 billion during the quarter, compared to the consensus estimate of $1.09 billion. BioNTech had a trailing twelve-month return on equity of 32.52% and a net margin of 51.03%. BioNTech's quarterly revenue was down 80.0% on a year-over-year basis. During the same quarter last year, the company earned $15.98 EPS. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and Loncar Cancer Immunotherapy ETF (CNCR). What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. What is BioNTech's stock symbol? BioNTech trades on the NASDAQ under the ticker symbol "BNTX." Who are BioNTech's major shareholders? BioNTech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.10%), Flossbach Von Storch AG (1.41%), Artisan Partners Limited Partnership (1.07%), BlackRock Inc. (0.79%), Envestnet Asset Management Inc. (0.40%) and Twin Tree Management LP (0.00%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioNTech's stock price today? One share of BNTX stock can currently be purchased for approximately $109.50. How much money does BioNTech make? BioNTech (NASDAQ:BNTX) has a market capitalization of $26.63 billion and generates $18.24 billion in revenue each year. The company earns $9.94 billion in net income (profit) each year or $26.01 on an earnings per share basis. How many employees does BioNTech have? The company employs 4,530 workers across the globe. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More How can I contact BioNTech? BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390. This page (NASDAQ:BNTX) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.